| EPA0031 | Genetic signatures of HIV-infected CD4+ T cells that survive interactions with NK cells | E-poster | Host immune responses, vaccines and immunotherapies |
| EPA0032 | Autophagy and the acyl-coA-binding protein influence immune function in people living with HIV | E-poster | Host immune responses, vaccines and immunotherapies |
| EPA0033 | Epistatic interaction of host immune factors modulates disease outcome following HIV infection | E-poster | Host immune responses, vaccines and immunotherapies |
| EPA0034 | Improvement of B cell responses by an HIV-1 amphiphilic polymer nanovaccine | E-poster | Host immune responses, vaccines and immunotherapies |
| EPA0035 | HIV-infected macrophages express different NK ligands compared to HIV-infected T cells | E-poster | Host immune responses, vaccines and immunotherapies |
| EPA0036 | Pomalidomide drives expansion of HIV-specific CD8+ T-cells by promoting transcriptional activity of E2F1 and PRMT3 | E-poster | Host immune responses, vaccines and immunotherapies |
| EPA0037 | Zinc protein inhibitor SAMT-247 modulate immune response generated by ALVAC-based HIV vaccine candidate and improve the vaccine efficacy | E-poster | Host immune responses, vaccines and immunotherapies |
| EPA0038 | Duration of antiretroviral therapy is a determinant of the frequency of NKG2C+CD57+ adaptive NK cells in persons living with cytomegalovirus and HIV infections | E-poster | Host immune responses, vaccines and immunotherapies |
| EPA0039 | IL-15 treatment rescues perturbations to NK cell mitochondrial fitness and effector function driven by acute SIV infection | E-poster | Host immune responses, vaccines and immunotherapies |
| EPA0040 | Ibalizumab and CD4 domain 2 exert an allosteric effect on HIV envelope binding to CD4 domain1 | E-poster | Host immune responses, vaccines and immunotherapies |